# Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer

> **NCT00377559** · PHASE2 · COMPLETED · sponsor: **Catharina Ziekenhuis Eindhoven** · enrollment: 70 (actual)

## Conditions studied

- Breast Cancer
- Neoplasm Metastasis

## Interventions

- **DRUG:** Non pegylated liposomal doxorubicin and docetaxel

## Key facts

- **NCT ID:** NCT00377559
- **Lead sponsor:** Catharina Ziekenhuis Eindhoven
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2009-11
- **Final completion:** 2011-07
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2015-10-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00377559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00377559, "Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00377559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*